Chung-Tsen Hsueh

Presentations 

  General Academic Presentation

• 10/24/10 BIT Life Sciences'' 1st Annual NanoMedicine Conference, October 23-25, 2010, Beijing, China, “Nanovectors for anti-cancer drug delivery: from research to clinical practice”. ( 10/2010 )

• 05/14/10 Lung Cancer Symposium at UC Irvine, “Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 as prognostic markers in NSCLC” ( 5/2010 )

  Research Presentations -- International

• Liao, Y.-M.; Mirshahidi, H.; Zhang K.; Mirshahidi, S.; Williamson, S.; Hsueh, C.-T. Phase I study of azacitidine and cisplatin in patients with advanced head and neck or non-small cell lung cancer. Proc. Am. Assoc. Cancer Res. 53: abstract# 2663, 2012. ( 4/2012 )

• Hsueh, C.-T. Targeted therapy in head/neck and gastric cancers. New developments in Hematology and Oncology. December 25-26, 2011. Guangzhou, China. ( 12/2011 ) Link...

• Huang, C.H.; Williamson, S.K.; VanVeldhuizen, P.J.; Hsueh, C.-T.; Allen, A.; Smith, H.; Mayo, M.; Tawfik, O.; Uypeckcuat, A.M.; Kelly, K. PDGFR inhibition using imatinib combined with docetaxel, a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer: Preliminary efficacy results. Proc. Am. Soc. Clin. Oncol. 26: abstract# 19055, 2008.   ( 6/2008 )

• Hsueh, E.C.; Knebel, S.M.; Hsueh, C.-T.; Leung, Y.-C.; Lo, W.-H.; Cheng, P.N. Mechanism of decreased cell viability in prostate cancer cell lines following arginine depletion. Proc. Am. Assoc. Cancer Res. 49: abstract# 4363, 2008. ( 4/2008 )

• Hsueh, E.C.; Knebel, S.M.; Hsueh, C.-T.; Leung, Y.-C.; Lo, W.-H.; Cheng, P.N. Defect in urea cycle sensitizes melanoma cells to arginine depletion. Journal of Surgical Research, 144: 308-309. Academic Surgical Congress February 12-15, 2008, at the Hyatt Regency Huntington Beach Resort & Spa in Huntington Beach, California. ( 2/2008 )

• Huang, C.H.; Williamson, S.K.; Van Veldhuizen, P.J.; Hsueh, C.-T.; Allen, A.; Smith, H.; Mayo, M.; Kelly, K. The potential role of PDGFR inhibition using imatinib with docetaxel in the treatment of recurrent non-small cell lung cancer. J. Thorac. Oncol. 2(8) Supplement 4: p S722, 2007 12th World Conference on Lung Cancer. ( 9/2007 )

• 04/19/05 Annual Meeting of American Association for Cancer Research. Philadelphia, Pennsylvania. The role of bile acids in cellular invasiveness of gastric cancer. (poster presentation). ( 4/2005 - Present )

• 03/05/02 Cancer Trials in Asia – The 7th Annual Scientific Symposium of the Hong Kong Cancer Institute, Hong Kong. An open-label study to investigate the  pharmacokinetics of Formoxol® (paclitaxel) in Chinese patients with metastatic breast cancer. (poster presentation) ( 3/2002 - Present )

• 09/24/00 Aventis Campto Symposium. Singapore. Current chemotherapy in colorectal cancer. (oral presentation) ( 9/2000 - Present )

• 11/17/99 AACR-NCI-EORTC International Conference – Molecular Targets and Cancer Therapeutics. Washington, DC. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. (poster presentation) ( 11/1999 - Present )

• 05/15/99 Therapeutics Against Novel Targets Session of Annual Meeting of American Society of Clinical Oncology. Atlanta, Georgia. Selective inhibition of cyclooxygenase-2 enhances chemotherapy-induced apoptosis. (poster presentation) ( 5/1999 - Present )

• 04/12/99 Annual Meeting of American Association for Cancer Research. Philadelphia, Pennsylvania. UCN-01 enhances 5-fluorouracil-induced apoptosis through caspase activation and ubiquitin-proteasome-dependent degradation of E2F-1. (poster  presentation) ( 4/1999 - Present )

• 10/15/98 American Association for Cancer Research Special Conference on "Gene Regulation and Cancer". Hot Springs, Virginia. UCN-01 suppresses thymidylate synthase gene expression mediated mainly by down-regulation of E2F-1 and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. (poster presentation) ( 10/1998 - Present )

• 05/19/98 New Approaches in Drug Development Session of Annual Meeting of American Society of Clinical Oncology. Los Angeles, California.UCN-01 suppresses thymidylate synthase and dihydrofolate reductase gene expression mediated by down- regulation of E2F-1 in human gastric cancer cells. (oral presentation) ( 5/1998 - Present )

  Research Presentations -- National

• Olivier Rixe, O.; Sarantopoulos, J.; Hsueh, C.-T.; Lockhart, A.C.; Ross, S.; Agarwala, S.S.; Zhang, W.; Yin, J.Y.; Wack, C.; Mazuir, F.; Gurtler, J.S. Absence of interaction of cabazitaxel on the pharmacokinetics of midazolam: Results of a drug–drug interaction study in patients with advanced solid tumors. J Clin Oncol 31, 2013 (suppl 6; abstr 126). 2013 Genitourinary Cancers Symposium in Orlando, Florida. February 14-16, 2013  ( 2/2013 - 4/2019 ) Link...

• 02/29/04 Academic Seminar of Central Taiwan, Chinese Oncology Society, Taiwan. Taichung, Taiwan. Overview of hormonal therapy in metastatic breast cancer ( 2/2004 - Present )

• 12/20/03 AstraZeneca Putting Progress into Practice. Taipei, Taiwan. Recent progress in hormonal therapy for breast cancer. ( 12/2003 - Present )

• 10/04/03 The General Clinical Research Center, ICH-GCP Symposium. Taichung, Taiwan. Monitoring and reporting adverse event. ( 10/2003 - Present )

• 09/20/03 The General Clinical Research Center, ICH-GCP Symposium. Taichung, Taiwan. 1. International conference on harmonization-good clinical practice. 2. Informed consent form. ( 9/2003 - Present )

• 03/12/03 Basic Oncology Nursing Training Course, the Oncology Nursing Society of Taiwan. Taichung, Taiwan. Principle and application of cancer chemotherapy. ( 3/2003 - Present )

• 02/23/03 Aventis Central NSP Training Program. Changhua, Taiwan. Hormonal therapy and chemotherapy for breast cancer. ( 2/2003 - Present )

• 12/18/02 The General Clinical Research Center, Related Audit System and Institutional Review Board for Hunan Research at Medical Center Symposium. Taichung, Taiwan. The roles of principal investigator in clinical trial. ( 12/2002 - Present )

• 11/24/02 AstraZeneca the Role of Hormone Therapy in the Treatment of Breast Cancer Symposium. Taoyuan, Taiwan. Management of metastatic breast cancer: an evidence-based approach. ( 11/2002 - Present )

• 06/01/02 Academic Seminar of Central Taiwan, Chinese Oncology Society, Taiwan. Changhua, Taiwan. Update in chemotherapy for metastatic colorectal cancer. ( 6/2002 - Present )

• 05/03/02 Aventis Campto Night. Taichung, Taiwan. CPT-11 in colorectal cancer. ( 5/2002 - Present )

• 12/08/01 Fifth Annual Meeting of Taiwan Cooperative Oncology Group in Conjunction with Cross Taiwan Strait Symposium on Cancer Therapeutics. Taipei, Taiwan. Cyclooxygenase-2 as a target in cancer prevention and treatment. ( 12/2001 - Present )

• 12/22/01 Quality Improvement on Resident’s Medical Record Writing Symposium. Tainan, Taiwan. Basic principles of medical record writing. ( 12/2001 - Present )

• 11/03/01 Academic Seminar of Central Taiwan, Chinese Oncology Society, Taiwan. Miaoli, Taiwan. Update on cyclin-dependent kinase inhibitors. ( 11/2001 - Present )

• 08/04/01 Novartis Oncology Symposium. Chiayi, Taiwan. Overview of biphosphonates. ( 8/2001 - Present )

• 06/02/01 Continuing Education Core Courses, Taiwanese Geriatric Society. Taichung, Taiwan. 1. Oncology in the elderly.  2. Palliative medicine; death and dying. ( 6/2001 - Present )

• 05/09/01 Advanced Oncology Nursing Training Course, the Oncology Nursing Society of Taiwan. Taichung, Taiwan. Current status and future direction of cancer chemotherapy. ( 5/2001 - Present )

• 03/24/01 AstraZeneca Hormone Therapy in the Treatment of Breast Cancer Symposium. Taoyuan, Taiwan. Systemic therapy in postmenopausal women with breast cancer. ( 3/2001 - Present )

• 10/01/00 Blood Bank Technician Continuing Education Program. Taiwanese Transfusion Medicine Society. Taichung, Taiwan. Clinical conditions associated with transfusion ( 10/2000 - Present )

• 09/10/00 Pharmacist Continuing Education Program. Taichung, Taiwan. New concept in cancer                therapeutics. ( 9/2000 - Present )

• 11/24/99 Basic Oncology Nursing Training Course, the Oncology Nursing Society of Taiwan. Taichung, Taiwan. Principle and application of cancer chemotherapy. ( 11/1999 - Present )

• 03/14/99 SmithKline Beecham National Oncology Fellows’ Forum. Miami, Florida. Selective inhibition of cyclooxygenase-2 enhances chemotherapy-induced apoptosis. ( 3/1999 - Present )

• 03/07/98 SmithKline Beecham National Oncology Fellows’ Forum. Tucson, Arizona. UCN-01 suppresses thymidylate synthase and dihydrofolate reductase gene expression in human gastric cancer cells. ( 3/1998 - Present )

  Research Presentations -- Local/Campus

• 04/25/06 Oncology Nursing Society-Kansas City, “Head and neck cancer: treatment modalities and side effects” (30 min presentation, estimated preparation time: 40 h, 50 oncology nurses audience). ( 4/2006 - Present )

• 12/14/05 KUMC Internal Medicine grandround, “Best of oncology” (50 min presentation, estimated preparation time: 40 h, 75 staffs/residents/students). ( 12/2005 - Present )

• 10/27/05 KUMed Colon Cancer Survivors’ Program, “Current colon cancer chemotherapy” (30 min presentation, estimated preparation time: 40 h, 50 lay audience members). ( 10/2005 - Present )

• 08/29/05 KU MedWest community wellness program, “Head and neck cancer” (1 h presentation, 40 h preparation, 20 lay audience members) ( 8/2005 - Present )

• 06/04/05 ASCO 2005 Review, KUMC Continuing Education, “Head and neck cancer” (40 min presentation, estimated preparation time: 40 h, 150 audience members). ( 6/2005 - Present )

• 04/30/05 Saturday Morning at KU Med Program, “Targeted therapies” (1 h presentation, estimated preparation time: 40 h, 200-400 lay audience members). ( 4/2005 - Present )

• 03/24/05 Western Missouri Medical Center community program in the surrounding area of    Warrensburg, “Colorectal cancer” ((1 h presentation, estimated preparation time: 40 h,    50-100 lay audience members). ( 3/2005 - Present )

• 2/16/05 All-provider meeting of Jayhawk Primary Care, “Updates in cancer” (30 min presentation, 5 h preparation time,  50 members). ( 2/2005 - Present )

• 2/15/05 KUMC Surgery grand round, “Targeted therapy for cancer” (40 h preparation, 1 h presentation, 50-75 staffs/residents/students) ( 2/2005 - Present )

  Presentations given to non-academic audiences

• Patient support group lecture: Support/education/awareness (SEA) for those living with neuroendocrine/carcinoid tumors at Glendale Adventist Medical Center, ”CSOM230C2303 Pasireotide (SOM230) LAR vs. Octreotide LAR” (1-h on 07/18/09) ( 7/2009 ) Link...